A Phase 1 Study to Evaluate H3B-8800 in Participants With Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia



Status:Recruiting
Conditions:Blood Cancer, Blood Cancer, Blood Cancer, Blood Cancer, Hematology
Therapuetic Areas:Hematology, Oncology
Healthy:No
Age Range:18 - Any
Updated:2/24/2019
Start Date:October 6, 2016
End Date:December 1, 2019
Contact:Eisai Medical Information
Email:esi_oncmedinfo@eisai.com
Phone:1-888-274-2378

Use our guide to learn which trials are right for you!

An Open-label, Multicenter Phase 1 Trial to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Splicing Modulator H3B-8800 for Subjects With Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia

This is a Phase 1, open-label, first-in-human (FIH) study designed to evaluate the safety,
tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary activity of
H3B-8800 in participants with Myelodysplastic Syndromes (MDS), Acute Myeloid Leukemia (AML),
or Chronic Myelomonocytic Leukemia (CMML). The study consists of two parts, a dose escalation
part (Part 1) and an expansion part (Part 2) exploring a multiple once daily (QD) schedules
at the recommended phase 2 dose (RP2D).


Inclusion Criteria:

1. Confirmed diagnosis of MDS, CMML, or AML.

2. The participant must meet the following criteria relevant to their specific diagnosis:

A. Participants with higher-risk MDS/CMML must be intolerant of hypomethylating agents
(HMAs) or not have responded to 4 treatment cycles of decitabine or 6 treatment cycles
of azacitidine, or must have progressed at any point after initiation of an HMA.

B. Participants with lower-risk MDS/CMML must be transfusion-dependent for red blood
cells or platelets (as determined by instructional practices or local standard of
care). Participants who are red blood cell transfusion-dependent must also have failed
erythropoiesis stimulating agents (ESA) (primary resistance or relapse after a
response) or have serum EPO levels > 500 U/L. These lower-risk participants must have
platelet counts above 50,000 mm^3 in the absence of transfusion for 8 weeks.

C. Participants with AML must either refuse or not be considered candidates for
intensive induction chemotherapy using consensus criteria for defining such
participants. Previously treated participants should have evidence of persistent or
recurrent AML in the peripheral blood and/or bone marrow that is refractory to, or has
relapsed from, their most recent prior line of treatment. For AML, participants must
have WBC < 15 × 10^9/L.

D. Participants with CMML must have been treated with at least one prior therapy
(hydroxyurea or a hypomethylating agent [HMA]).

3. Eastern Cooperative Oncology Group (ECOG) performance score of 0-2.

4. Adequate baseline organ function

Exclusion Criteria:

1. Diagnosis of a core binding factor leukemia (t(8;21), t(16;16) or inv(16)).

2. Participant is candidate for hematopoietic stem cell transplants at the time of
enrollment.

3. Family history of Leber Hereditary Optic Neuropathy, Autosomal Dominant Optic Atrophy,
Late-Onset Retinal Degeneration, Familial Dysautonomia or other hereditary
mitochondrial disease, unless the causative mutation(s) in the family have been
determined and the participant has tested negative for the mutation(s).

4. Known prior or current retinal or optic nerve disease (example, Retinitis Pigmentosa,
diabetic retinopathy, optic neuritis) based on screening ophthalmology assessment for
eligibility.

5. Corrected vision is worse than 20/40 unless due to cataracts.

6. Vitamin B12, folate or vitamin A deficiency. Rescreening following repletion therapy
is acceptable.
We found this trial at
19
sites
9500 Euclid Avenue
Cleveland, Ohio 44106
216.444.2200
Cleveland Clinic Cleveland Clinic is committed to principles as presented in the United Nations Global...
?
mi
from
Cleveland, OH
Click here to add this to my saved trials
185 Cambridge Street
Boston, Massachusetts 02114
617-724-5200
?
mi
from
Boston, MA
Click here to add this to my saved trials
330 Brookline Ave
Boston, Massachusetts 02215
617-667-7000
Beth Israel Deaconess Medical Center Beth Israel Deaconess Medical Center (BIDMC) is one of the...
?
mi
from
Boston, MA
Click here to add this to my saved trials
Chapel Hill, North Carolina 27599
(919) 962-2211
University of North Carolina at Chapel Hill Carolina’s vibrant people and programs attest to the...
?
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
5801 South Ellis Avenue
Chicago, Illinois 60637
 773.702.1234
University of Chicago One of the world's premier academic and research institutions, the University of...
?
mi
from
Chicago, IL
Click here to add this to my saved trials
Miami, Florida 33124
(305) 284-2211
University of Miami A private research university with more than 15,000 students from around the...
?
mi
from
Miami, FL
Click here to add this to my saved trials
1100 Fairview Avenue North
Seattle, Washington 98109
(206) 667-5000
Fred Hutchinson Cancer Research Center At Fred Hutchinson Cancer Research Center, our interdisciplinary teams of...
?
mi
from
Seattle, WA
Click here to add this to my saved trials
12902 USF Magnolia Dr
Tampa, Florida 33612
(888) 663-3488
H. Lee Moffitt Cancer Center & Research Institute Moffitt Cancer Center in Tampa, Florida, has...
?
mi
from
Tampa, FL
Click here to add this to my saved trials
450 Brookline Ave
Boston, Massachusetts 2215
617-632-3000
Dana-Farber Cancer Institute Since it’s founding in 1947, Dana-Farber has been committed to providing adults...
?
mi
from
Boston, MA
Click here to add this to my saved trials
Buffalo, New York 14263
?
mi
from
Buffalo, NY
Click here to add this to my saved trials
Denver, Colorado 80218
?
mi
from
Denver, CO
Click here to add this to my saved trials
Detroit, Michigan 48201
?
mi
from
Detroit, MI
Click here to add this to my saved trials
Houston, Texas 77030
?
mi
from
Houston, TX
Click here to add this to my saved trials
Jacksonville, Florida 32216
?
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Nashville, Tennessee 37203
?
mi
from
Nashville, TN
Click here to add this to my saved trials
1275 York Ave
New York, New York 10021
(212) 639-2000
Memorial Sloan Kettering Cancer Center Memorial Sloan Kettering Cancer Center — the world's oldest and...
?
mi
from
New York, NY
Click here to add this to my saved trials
Rochester, Minnesota 55905
?
mi
from
Rochester, MN
Click here to add this to my saved trials
Stanford, California 94305
?
mi
from
Stanford, CA
Click here to add this to my saved trials
Villejuif, Val-de-Marne 94805
?
mi
from
Villejuif,
Click here to add this to my saved trials